Search for


TEXT SIZE

search for



CrossRef (0)
씪諛섑솕븰 봽濡쒓렇옩 떊鍮숇룄議곗궗 寃곌낵蹂닿퀬(2017)
Annual Report on the External Quality Assessment Scheme for General Chemistry in Korea (2017)
J Lab Med Qual Assur 2018;40:113-127
Published online September 30, 2018
© 2018 Korean Association of External Quality Assessment Service.

씠슜솕
Yong-Wha Lee

닚泥쒗뼢븰援 쓽怨쇰븰 닚泥쒗뼢븰援먮泥쒕퀝썝 吏꾨떒寃궗쓽븰怨

Department of Laboratory Medicine & Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
Correspondence to: Yong-Wha Lee Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea Tel: +82-32-621-5943 Fax: +82-32-621-5944 E-mail: lywmd@schmc.ac.kr
援먯떊옄: 씠슜솕 슦)14584 寃쎄린룄 遺泥쒖떆 썝誘멸뎄 議곕쭏猷⑤줈 170, 닚泥쒗뼢븰援 쓽怨쇰븰 닚泥쒗뼢븰援먮泥쒕퀝썝 吏꾨떒寃궗쓽븰怨 Tel: 032)621-5943, Fax: 032)621-5944, E-mail: lywmd@schmc.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract

2017뀈 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽뿉꽌 엫긽솕븰遺꾩빞뿉뒗 슂솕븰寃궗 봽濡쒓렇옩씠 異붽릺뼱 珥 24媛쒖쓽 봽濡쒓렇옩쑝濡 援ъ꽦릺뿀떎. 씪諛섑솕븰寃궗 봽濡쒓렇옩 궪닾븬(osmolality), 珥 씠궛솕깂냼(total CO2) 異붿젙 궗援ъ껜뿬怨쇱쑉寃궗媛 異붽맂 珥 32媛쒖쓽 寃궗빆紐⑹쑝濡 援ъ꽦릺뿀怨, 슂솕븰寃궗 봽濡쒓렇옩 븣遺誘쇨궗 벑 珥 12媛쒖쓽 寃궗빆紐⑹쑝濡 援ъ꽦릺뿀떎. 媛 湲곌뿉꽌 엯젰맂 寃궗빆紐⑹뿉 븳 젙蹂댁 寃곌낵瑜 湲곕컲쑝濡 寃궗諛⑸쾿, 湲곌린, 떆빟뿉 뵲瑜 넻怨꾨텇꽍 옄猷뚭 蹂닿퀬릺룄濡 븯떎. 젣떆맂 넻怨꾩뿉뒗 媛 洹몃9蹂 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂씠怨꾩닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪씠 룷븿릺룄濡 븯怨 媛쒕퀎蹂닿퀬꽌뒗 媛 寃궗빆紐⑸퀎濡 넻怨꾩튂瑜 蹂댁뿬二쇰뒗 몴, 엳뒪넗洹몃옩, 젅鍮-젣떇뒪 李⑦듃 몴以렪李⑥닔濡 援ъ꽦릺룄濡 븯떎. 1,000媛 씠긽쓽 湲곌씠 李몄뿬븯뒗 寃궗빆紐⑹ 븣遺誘 벑 珥 14媛쒖쓽 寃궗빆紐⑹뿉 빐꽌 1,000媛 씠긽쓽 湲곌씠 李멸븯怨 엳怨 李멸湲곌 닔媛 吏냽쟻쑝濡 利앷븯뒗 異붿꽭씠떎. 蹂씠怨꾩닔뒗 媛 寃궗빆紐⑸퀎 쉶李⑤퀎濡 젙룄愿由щЪ吏덉쓽 냽룄媛 궙쓣닔濡 넂 寃쏀뼢쓣 蹂댁쑝굹 遺遺 10% 씠궡쓽 蹂씠怨꾩닔瑜 蹂댁떎. 븣移쇰━씤궛遺꾪빐슚냼(alkaline phosphatase) 젚궛깉닔냼슚냼(lactate dehydrogenase)뒗 寃궗踰 媛꾩뿉 寃곌낵쓽 李⑥씠媛 쑀쓽븯寃 而ㅼ꽌 蹂씠怨꾩닔룄 긽쟻쑝濡 留ㅼ슦 겙 寃껋쑝濡 愿李곕릺뿀떎. 씪諛섑솕븰寃궗빆紐⑹뿉 엳뼱꽌 痢≪젙踰뺤쓽 遺꾪룷뒗 쟾泥댁쟻쑝濡 쟾뀈룄 겙 李⑥씠뒗 뾾뿀怨, 슂솕븰寃궗빆紐 以 븣遺誘, 룷룄떦, 씤(phosphorus), 떒諛깆 痢≪젙踰뺤쓽 遺꾪룷媛 씪諛섑솕븰寃궗 李⑥씠媛 엳뿀떎.

In 2017, the clinical chemistry proficiency testing program consisted of 24 programs with the addition of the urine chemistry program in the Korean Association of External Quality Assessment Service. The routine chemistry program consisted of 32 test items, including osmolality, total CO2, and estimated glomerular filtration rate tests, and the urine chemistry program consisted of 12 test items, including the albumin test. Based on the information and results of each test item entered by each institution, statistical analysis data according to test method, instrument, and reagent were reported. The statistics included the number of participating institutions, mean, standard deviation, coefficient of variation, median, minimum, and maximum values 뗢땏or each group. Each report was composed of a table, histogram, Levy-Jennings chart, and standard deviation index showing statistics by each test item. A total of 14 items, including albumin, were evaluated by more than 1,000 institutions, and the number of participating institutions is continuously increasing. The coefficient of variation tended to increase, as the concentration of the control material was lower for each test item. Most of them showed a coefficient of variation within 10%. Alkaline phosphatase and lactate dehydrogenase were found to have high coefficients of variation due to differences in measurement values between measurement methods. The distribution of measurement methods in general chemistry test items was not significantly different from that of previous years, and the distribution of measurement methods for albumin, glucose, phosphorus, and protein among the urine chemistry program was different from that of the routine chemistry program.

Keywords : Proficiency testing, Clinical chemistry, Korean Association of External Quality Assessment Service
꽌 濡

븳엫긽寃궗젙룄愿由ы삊쉶뿉꽌뒗 2016뀈遺꽣 깉濡쒖슫 슫쁺諛⑹떇쓽 李⑥꽭 떊鍮숇룄議곗궗궗뾽쓣 떆뻾븯怨 엳떎. 媛옣 겙 蹂솕뒗 6媛 遺꾨쪟븯뿉 46媛 봽濡쒓렇옩 떒쐞蹂 슫쁺泥닿퀎濡 쟾솚븯뿬 寃궗빆紐⑹쓣 솗븳 젏씠 릺寃좊떎[1-3]. 2017뀈룄뿉뒗 엫긽솕븰 遺꾩빞뿉뒗 3媛쒖쓽 봽濡쒓렇옩씠 異붽릺뼱 씪諛섑솕븰寃궗 봽濡쒓렇옩쓣 鍮꾨’븯뿬 珥 24媛쒖쓽 봽濡쒓렇옩쑝濡 援ъ꽦릺뿀떎. 씪諛섑솕븰寃궗 봽濡쒓렇옩뿉뒗 궪닾븬(osmolality)寃궗 珥 씠궛솕깂냼(total CO2)寃궗媛 異붽릺뿀怨 3쉶李⑤꽣 꽦씤怨 냼븘쓽 異붿젙 궗援ъ껜뿬怨쇱쑉寃궗媛 떆踰붿궗뾽쑝濡 異붽릺뼱 珥 32媛쒖쓽 寃궗빆紐⑹쑝濡 솗릺뿀떎. 삉븳 씪諛섑솕븰寃궗 봽濡쒓렇옩 쇅뿉 슂솕븰寃궗 봽濡쒓렇옩씠 떊꽕릺뼱 븣遺誘쇨궗 벑 珥 12媛쒖쓽 寃궗빆紐⑹뿉 븳 떊鍮숇룄議곗궗媛 2쉶뿉 嫄몄퀜 떆뻾릺뿀떎.

옄뱾 2017뀈 븳엫긽寃궗젙룄愿由ы삊쉶쓽 떊鍮숇룄議곗궗궗뾽쑝濡 떎떆릺뿀뜕 씪諛섑솕븰寃궗 슂솕븰寃궗뿉 븳 떊鍮숇룄議곗궗궗뾽 寃곌낵瑜 遺꾩꽍븯뿬 蹂닿퀬븯怨좎옄 븳떎.

옱猷 諛 諛⑸쾿

1. 긽

씪諛섑솕븰寃궗 봽濡쒓렇옩 뿰 4쉶뿉 嫄몄퀜, 쉶李⑤퀎濡 3媛쒖쓽 젙룄愿由щЪ吏덉씠 씠슜릺뼱 떆뻾릺뿀떎. 臾쇱쭏 깋옣긽깭媛 쑀吏맆 닔 엳룄濡 븘씠뒪뙥씠 궡옣맂 듅닔 젣옉諛뺤뒪뿉 꽔뼱 李몄뿬 벑濡앷린愿쓣 긽쑝濡 1쉶李⑥ 2쉶李⑤뒗 3썡 27씪뿉 諛쒖넚릺뿀怨 3쉶李⑥ 4쉶李⑤뒗 10썡 16씪뿉 諛쒖넚릺뿀떎. 슂솕븰寃궗 봽濡쒓렇옩 뿰 2쉶뿉 嫄몄퀜 쉶李⑤퀎濡 3媛쒖쓽 젙룄愿由щЪ吏덉씠 씠슜릺뿀怨 1쉶李⑥ 2쉶李⑤ 媛곴컖 6썡 13씪怨 9썡 18씪뿉 諛쒖넚븯떎.

2. 젙룄愿由щЪ吏덇낵 寃궗빆紐

씪諛섑솕븰寃궗쓽 젙룄愿由щЪ吏덉 궗엺 삁泥쓣 湲곗쭏濡 븳 遺꾨쭚젣뭹씤 Randox궗(London, UK) Bio-Rad궗(Bio-Rad Laboratories, Hercules, CA, USA)쓽 궗엺 삁泥쓣 湲곗쭏濡 븳 遺꾨쭚젣뭹쓣 궗슜븯떎(Table 1). 寃궗빆紐⑹ 1쉶李⑥ 2쉶李⑤뒗 珥 30빆紐⑹씠뿀怨 3쉶李⑥ 4쉶李⑤뒗 꽦씤怨 냼븘쓽 異붿젙 궗援ъ껜뿬怨쇱쑉 빆紐⑹씠 異붽릺뼱 珥 32빆紐⑹씠뿀떎. 슂솕븰寃궗쓽 젙룄愿由щЪ吏덉 Bio-Rad궗쓽 Lyphochek Quantitative Urine Control쓣 궗슜븯떎. 寃궗빆紐⑹ 븣遺誘 벑 珥 12빆紐⑹씠뿀떎(Table 2). 궗쟾뿉 怨듭맂 씪젙뿉 뵲씪 臾쇱쭏쓣 닔졊븳 李몄뿬湲곌뿉꽌뒗 寃궗 떆뻾 썑 吏젙맂 쉶떊 留덇컧씪 씠궡뿉 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽 솃럹씠吏(http://eqas.keqas.org)뿉 寃곌낵瑜 엯젰븯룄濡 븯떎. 湲곌린쉶궗 떆빟쉶궗濡쒕꽣 젣怨듬맂 寃궗빆紐⑸퀎 寃궗諛⑸쾿, 湲곌린 떆빟뿉 빐 湲곗큹옄猷뚮 寃넗븳 諛붾 넗濡 李몄뿬湲곌씠 솃럹씠吏긽뿉꽌 빐떦 寃궗빆紐⑹뿉 븳 寃궗젙蹂 꽑깮怨 寃곌낵 엯젰씠 媛뒫븯룄濡 쟾궛泥닿퀎瑜 援ъ텞븯떎.

Table 1 . Control materials provided for analysis and released dates from the routine chemistry trials in 2017.

TrialMaterial no.Manufacturer꺿꺿긑roduct name꺿긌ot no.Released date
1stCC-17-01Randox*Human low serum 5 mL level 1229ULCM
CC-17-02RandoxHuman norm serum 5 mL level 21128UN27 March
CC-17-03RandoxHuman Elev serum 5 mL level 3875UE
2ndCC-17-04RandoxHuman low serum 5 mL level 1256ULCM
CC-17-05RandoxHuman norm serum 5 mL level 21090UN27 March
CC-17-06RandoxHuman Elev serum 5 mL level 3845UE
3rdCC-17-07Bio-RadLyphochek assayed & unassayed chemistry control28811 (level 1)
CC-17-08Bio-RadLyphochek assayed & unassayed chemistry control26441 (level 2)16 October
CC-17-09Bio-RadLyphochek assayed & unassayed chemistry control26442 (level 3)
4thCC-17-10Bio-RadLyphochek assayed & unassayed chemistry control26431 (level 1)
CC-17-11Bio-RadLyphochek assayed & unassayed chemistry control26432 (level 2)16 October
CC-17-12Bio-RadLyphochek assayed & unassayed chemistry control28812 (level 3)

*Randox Laboratories (London, UK),

Bio-Rad Laboratories (Hercules, CA, USA).


Table 2 . Control materials provided for analysis and released dates from the urine chemistry trials in 2017.

TrialMaterial no.Manufacturer꺿꺿긑roduct name꺿긌ot no.Released date
1stCUC-17-01Bio-Rad*Lyphochek quantitative urine control63371 (level 1)
CUC-17-02Bio-RadLyphochek quantitative urine control63381 (level 1)13 June
CUC-17-03Bio-RadLyphochek quantitative urine control63382 (level 2)
2ndCUC-17-04Bio-RadLyphochek quantitative urine control63391 (level 1)
CUC-17-05Bio-RadLyphochek quantitative urine control63392 (level 2)18 September
CUC-17-06Bio-RadLyphochek quantitative urine control63372 (level 2)

*Bio-Rad Laboratories (Hercules, CA, USA).


3. 寃곌낵 뙋젙 諛 遺꾩꽍

씪諛섑솕븰寃궗 슂솕븰寃궗 媛곴컖뿉 빐꽌 媛 湲곌뿉꽌 엯젰븳 媛 寃궗빆紐⑹뿉 븳 젙蹂댁 寃곌낵瑜 湲곕컲쑝濡 寃궗諛⑸쾿, 湲곌린, 떆빟뿉 뵲씪 넻怨꾨텇꽍쓣 떆뻾븯怨 씠瑜 쟾泥 李몄뿬湲곌쓽 듅꽦쓣 蹂댁뿬二쇰뒗 怨듯넻蹂닿퀬꽌 媛쒕퀎湲곌쓽 룊媛옄猷뚮 蹂댁뿬二쇰뒗 湲곌蹂 蹂닿퀬꽌濡 굹늻뼱 蹂닿퀬븯떎. 怨듯넻蹂닿퀬꽌뒗 3떒怨꾨줈 洹몃9솕븯뿬 넻怨꾩튂瑜 젣떆븯떎. 쟾泥 李몄뿬湲곌뿉 빐떦븯뒗 넻怨, 寃궗諛⑸쾿쓣 湲곗遺꾨쪟濡 븳 洹몃9쓽 넻怨꾩 寃궗諛⑸쾿蹂꾨줈 떆빟쉶궗瑜 꽭遺꾨쪟븳 洹몃9쓽 넻怨꾨 媛곴컖 젣떆븯떎.

젣떆맂 넻怨꾩뿉뒗 媛 洹몃9蹂 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂룞怨꾩닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪씠 룷븿릺룄濡 븯怨 李몄뿬湲곌 닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪 씠긽移섎 젣嫄고븯吏 븡 닔移섎 젣떆븯怨 룊洹, 몴以렪李⑥ 蹂룞怨꾩닔뒗 媛 洹몃9蹂꾨줈 씠긽移섎 젣嫄고븳 썑 궛異쒕맂 닔移섎 궗슜븯떎. 삉븳 빐떦 遺꾨쪟뿉 냽븳 湲곌 닔媛 10媛 誘몃쭔씤 寃쎌슦 룊洹, 몴以렪李⑥ 蹂룞怨꾩닔瑜 젣떆븯吏 븡븯怨 湲곌 닔媛 3媛 誘몃쭔씤 寃쎌슦 以묒븰媛믩룄 젣떆븯吏 븡븯떎. 씠긽移섎뒗 媛 빐떦 遺꾨쪟뿉꽌 75띁꽱씪 媛(Q3)怨 25띁꽱씪 媛(Q1)쓽 李(Q3-Q1, interquartile range [IQR])쓽 1.5諛곕 珥덇낵븯뿬 Q1蹂대떎 궙嫄곕굹 Q3蹂대떎 넂 寃곌낵媛(媛쒕퀎蹂닿퀬꽌뒗 媛 寃궗빆紐⑸퀎濡 넻怨꾩튂瑜 蹂댁뿬二쇰뒗 몴, 엳뒪넗洹몃옩怨 젅鍮-젣떇뒪 李⑦듃濡 援ъ꽦릺룄濡 븯떎. 넻怨꾩튂瑜 젣떆븳 몴뿉뒗 媛 湲곌쓽 寃곌낵媛믨낵 媛 遺꾨쪟蹂 넻怨꾩튂瑜 젣떆븯怨 湲곗遺꾨쪟 꽭遺꾨쪟뿉꽌뒗 몴以렪李⑥닔(standard deviation index, SDI)瑜 븿猿 젣떆븯떎. 쟾泥 寃곌낵뿉 빐꽌뒗 SDI瑜 젣떆븯吏 븡븯怨 媛 洹몃9뿉꽌 李멸湲곌쓽 닔媛 10媛 誘몃쭔씪 寃쎌슦 SDI瑜 젣떆븯吏 븡븯떎.

엳뒪넗洹몃옩뿉꽌뒗 쟾泥닿린愿쓽 遺꾪룷 湲곗遺꾨쪟蹂 遺꾪룷瑜 젣떆븯怨 媛 湲곌쓽 쐞移섎 몴떆븯떎. 엳뒪넗洹몃옩 20媛쒖쓽 留됰濡 援ъ꽦븯怨 泥 踰덉㎏ 留덉留 留됰뒗 媛곴컖 쟾泥 李몄뿬湲곌쓽 寃곌낵遺꾪룷뿉꽌 2.5띁꽱씪 誘몃쭔怨 97.5띁꽱씪 씠긽뿉 빐떦븯硫 以묎컙 留됰뱾 2.5띁꽱씪 媛믨낵 97.5띁꽱씪 媛믪쓽 踰붿쐞瑜 룞씪븳 媛꾧꺽쑝濡 굹늻뼱 遺꾪룷瑜 굹궡뿀떎. 젅鍮-젣떇뒪 李⑦듃뒗 湲곗遺꾨쪟蹂 SDI瑜 씠슜븯뿬 옉꽦븯떎.

寃곌낵 諛 怨좎같

2017뀈뿉뒗 4쉶뿉 嫄몄퀜 떆뻾맂 씪諛섑솕븰寃궗 봽濡쒓렇옩怨 2쉶뿉 嫄몄퀜 떆뻾맂 슂솕븰寃궗 봽濡쒓렇옩쓽 쇅遺젙룄愿由 遺꾩꽍寃곌낵媛 쉶李⑤쭏떎 異붽 媛엯 뿬遺뿉 뵲씪 李몄뿬湲곌 닔 쉶떊쑉씠 떖옄湲곗뿉 媛 봽濡쒓렇옩蹂꾨줈 留 쉶李⑤쭏떎 쉶떊맂 湲곌쓣 긽쑝濡 넻怨꾨텇꽍씠 릺뿀떎. 젙룄愿由щЪ吏덉 쉶李⑤쭏떎 媛곴컖 꽌濡 떎瑜 濡쒗듃踰덊샇瑜 媛뽯뒗 臾쇱쭏쓣 씠슜븯怨 쉶李⑤퀎濡 넂 냽룄 궙 냽룄媛 떎뼇븳 닚꽌濡 꽎씠룄濡 븯떎.

씪諛섑솕븰寃궗 봽濡쒓렇옩뿉꽌뒗 1,000媛 씠긽쓽 湲곌씠 李몄뿬븯뒗 寃궗빆紐⑹ 븣遺誘, 븣移쇰━씤궛遺꾪빐슚냼(alkaline phosphatase, ALP), 븣씪땶븘誘몃끂쟾씠슚냼(alanine amino異뾯ansferase, ALT), 븘뒪뙆瑜댄뀒씠듃븘誘몃끂쟾씠슚냼(aspartate aminotransferase, AST), 삁븸슂냼吏덉냼(blood urea nitrogen, BUN), 珥 肄쒕젅뒪뀒濡, 겕젅븘떚땶, 媛먮쭏湲猷⑦諛쟾씠슚냼(gamma-glutamyl transferase), 룷룄떦, 怨좊룄吏떒諛깆퐳젅뒪뀒濡(high-density lipoprotein cholesterol, HDL-C), 珥 떒諛, 珥 鍮뚮━猷⑤퉰, 以묒꽦吏諛⑷낵 슂궛(uric acid) 벑씠뿀怨 1쉶李⑥ 2쉶李⑥뿉 鍮꾪빐 3쉶李⑥ 4쉶李⑥쓽 李멸湲곌 닔媛 利앷븯떎(Table 3).

Table 3 . Number of laboratories that participated in each routine chemistry test in 2017.

꺿꺿긖estTrial

1st2nd3rd4th
Alanine transaminase1,4161,4201,5851,569
Albumin1,3021,3051,4631,447
Alkaline phosphatase1,2411,2441,4011,389
Amylase733733798788
Aspartate aminotransferase1,4151,4191,5841,568
Bilirubin, direct728725783774
Bilirubin, total1,3051,3081,4681,452
Calcium662664712702
Chloride876878986977
Cholesterol, total1,4071,4111,5721,557
Creatine kinase622614654652
Creatinine1,3561,3581,5241,514
Gamma-glutamyl transferase1,3851,3881,5401,525
Glucose1,4001,4031,5611,544
High density lipoprotein cholesterol1,3081,3091,4471,432
Iron388393408406
Lactate dehydrogenase831824886878
Lipase394392406400
Low density lipoprotein cholesterol834829903890
Magnesium269273284283
Osmolality129135143143
Phosphorus617617664658
Potassium888891999990
Protein, total1,2841,2901,4471,429
Sodium888890999990
Total CO2177185199199
Total iron-binding capacity350356371369
Triglyceride1,3791,3811,5311,516
Urea nitrogen1,3511,3501,5121,498
Uric acid1,1031,0981,2011,191
Estimated glomerular filtration rate (adult)280270
Estimated glomerular filtration rate (child)181166

슂솕븰寃궗 봽濡쒓렇옩뿉꽌뒗 겕젅븘떚땶寃궗뿉 李몄뿬븯뒗 湲곌씠 媛옣 留롮븯怨 1쉶李⑥뿉 鍮꾪빐 2쉶李⑥쓽 李멸湲곌 닔媛 留롮븯떎(Table 4).

Table 4 . Number of laboratories that participated in each urine chemistry test in 2017.

꺿꺿긖estTrial

1st2nd
Albumin123135
Calcium117131
Chloride131148
Creatinine142161
Glucose112123
Magnesium97101
Phosphorus114122
Potassium132149
Protein129144
Sodium132150
Urea nitrogen123136
Uric acid116127

씪諛섑솕븰寃궗 봽濡쒓렇옩뿉꽌 蹂씠怨꾩닔뒗 媛 寃궗빆紐⑸퀎 쉶李⑤퀎濡 긽쟻쑝濡 젙룄愿由щЪ吏덉쓽 냽룄媛 궙怨 李몄뿬湲곌쓽 닔媛 쟻쓣닔濡 넂 寃쏀뼢쓣 蹂댁떎(Table 5). 遺遺 10% 씠궡쓽 蹂씠怨꾩닔瑜 蹂댁吏留 ALP, 븘諛씪븘젣, 젚궛깉닔냼슚냼(lactate dehydrogenase, LD), 吏곸젒鍮뚮━猷⑤퉰, HDL-C, 諛룄吏떒諛깆퐳젅뒪뀒濡(low-density lipoprotein cholesterol)怨 以묒꽦吏諛 벑쓽 씪遺 諛⑸쾿뿉꽌 10% 씠긽쓽 넂 蹂씠怨꾩닔瑜 蹂댁떎. 臾쇰줎 룞씪븳 寃궗踰뺤쓣 궗슜븯뒗 洹몃9 궡뿉꽌뒗 鍮꾧탳쟻 옉 蹂씠怨꾩닔瑜 蹂댁쑝굹 ALP LD뒗 寃궗踰 媛꾩뿉 寃곌낵쓽 李⑥씠媛 쑀쓽븯寃 而ㅼ꽌 蹂씠怨꾩닔룄 긽쟻쑝濡 留ㅼ슦 겙 寃껋쑝濡 愿李곕릺뿀떎(Table 5).

Table 5 . Peer-group coefficients of variation (%) according to the test and trials of routine chemistry in 2017.

꺿꺿긖estTrial

CC-17-01CC-17-02CC-17-03CC-17-04CC-17-05CC-17-06CC-17-07CC-17-08CC-17-09CC-17-10CC-17-11CC-17-12
Alanine aminotransferase5.910.67.16.613.15.86.56.45.86.76.26.2
Albumin5.25.43.93.95.75.24.94.95.14.95.85.2
Alkaline phosphatase46.161.248.243.765.240.444.544.237.745.138.736.5
Amylase18.217.515.715.815.618.013.013.119.113.319.019.2
Aspartate aminotransferase5.25.56.76.49.35.45.45.24.46.14.74.6
Bilirubin, direct15.320.415.013.616.616.420.318.720.19.021.315.2
Bilirubin, total6.98.38.87.69.46.49.49.96.711.16.56.6
Calcium2.33.62.82.64.32.34.23.62.74.42.92.5
Chloride2.03.12.62.93.41.93.32.82.53.02.62.5
Cholesterol (total)2.63.12.92.73.22.93.03.04.92.95.24.8
Creatine kinase5.55.76.25.75.35.24.33.94.74.35.05.0
Creatinine5.012.96.95.710.55.214.011.57.912.37.78.0
Gamma-glutamyl transferase5.59.45.85.99.15.47.87.27.37.67.57.7
Glucose3.13.53.33.04.03.13.83.73.13.93.33.2
High density lipoprotein cholesterol21.627.47.57.031.412.614.210.813.312.614.513.6
Iron3.73.43.63.23.63.53.53.34.03.23.83.5
Lactate dehydrogenase37.937.937.037.836.638.336.037.740.036.140.340.3
Lipase12.015.611.811.211.211.47.54.914.07.015.316.2
Low density lipoprotein cholesterol29.339.215.115.241.122.58.08.48.98.08.27.2
Magnesium2.35.23.53.24.73.43.93.83.44.02.22.7
Osmolality1.21.61.61.31.21.41.61.31.11.41.31.3
Phosphorus3.35.43.22.04.93.22.53.52.32.32.42.7
Potassium1.63.81.91.94.71.51.91.92.21.91.61.5
Protein, total3.53.33.12.32.33.32.83.33.73.34.14.2
Sodium1.71.81.51.51.51.41.31.21.31.31.31.4
Total CO26.78.97.09.29.57.46.15.55.66.05.55.5
Total iron-binding capacity2.74.74.84.34.33.33.22.83.73.63.23.2
Triglyceride42.851.129.228.760.750.83.63.65.34.05.75.3
Urea nitrogen5.24.84.54.25.55.85.34.84.45.75.74.9
Uric acid4.37.24.74.35.94.44.14.13.74.14.13.7
Estimated glomerular filtration rate (adult)NA16.014.217.613.213.4
Estimated glomerular filtration rate (child)55.2NANANANANA

Abbreviation: NA, not applicable..


슂솕븰寃궗 봽濡쒓렇옩뿉꽌 媛 寃궗빆紐⑸퀎 蹂씠怨꾩닔뒗 遺遺 10% 씠궡쓽 媛믪쓣 蹂댁쑝굹 븣遺誘쇨낵 떒諛깆 긽쟻쑝濡 넂 蹂씠怨꾩닔瑜 蹂댁떎(Table 6). 蹂씠怨꾩닔뒗 媛 媛 湲곌쓽 긽쟻 쐞移섎 굹궡뒗 SDI룄 愿젴릺誘濡 蹂씠怨꾩닔媛 겙 寃쎌슦 SDI뒗 긽쟻쑝濡 옉븘吏 닔 엳쑝誘濡 寃곌낵빐꽍 떆 怨좊젮릺뼱빞 븳떎.

Table 6 . Peer-group coefficients of variation (%) according to the test and trials of urine chemistry in 2017.

꺿꺿긖estTrials

CUC-17-01CUC-17-02CUC-17-03CUC-17-04CUC-17-05CUC-17-06
Albumin36.138.023.649.622.923.3
Calcium3.63.13.03.52.52.4
Chloride8.19.33.18.62.72.8
Creatinine5.35.75.54.84.54.7
Glucose3.33.42.43.72.42.7
Magnesium3.54.56.33.44.14.9
Phosphorus3.03.13.32.82.72.9
Potassium2.22.54.02.44.04.3
Protein14.314.69.413.58.89.6
Sodium2.52.51.22.41.21.2
Urea nitrogen3.83.73.33.53.43.0
Uric acid4.85.64.34.63.73.6

씪諛섑솕븰寃궗빆紐⑹뿉 엳뼱꽌 痢≪젙踰뺤쓽 遺꾪룷뒗 쟾泥댁쟻쑝濡 쟾뀈룄 겙 李⑥씠뒗 뾾뿀怨, 븳 媛吏 寃궗諛⑸쾿씠 쟾泥댁쓽 80%瑜 꽆뒗 寃궗뒗 븣遺誘쇱쓽 dye binding bromocresol green踰, ALT AST쓽 ultra violet (UV) without pyridoxal-5-phosphate踰, BUN쓽 urease with glutamate dehydrogenase踰, 珥 肄쒕젅뒪뀒濡ㅼ쓽 슚냼痢≪젙踰, 굹듃瑜, 移쇰ⅷ怨 뿼냼 벑쓽 쟾빐吏덉쓽 ion selective electrode踰, 留덇렇꽕뒛쓽 鍮꾩깋踰(dye-xylidyl blue/magon), 珥 떒諛깆쓽 biuret踰뺢낵 슂궛쓽 uricase踰뺤씠뿀떎. 2017뀈룄뿉 異붽濡 떊꽕맂 궪닾븬怨 珥 씠궛솕깂냼寃궗룄 freezing point depression osmometer踰뺢낵 phosphoenolpyruvate carboxylase踰뺤씠 痢≪젙踰뺤쓽 遺遺꾩쓣 李⑥븯떎(Table 7).

Table 7 . Distribution of analytical methods (principle) participated and coefficients of variation (%) according to routine chemistry principles in 2017.

꺿꺿긆tems/methodsTrials

1st2nd3rd4th




Lab*CC-17-01CC-17-02CC-17-03LabCC-17-04CC-17-05CC-17-06LabCC-17-07CC-17-08CC-17-09LabCC-17-10CC-17-11CC-17-12
Alanine aminotransferase1,4151,4201,5851,569
긂nzymatic, colorimetric (Vitros)107.37.413.7107.110.41.31118.011.60.5117.51.01.0
긐ther method1047.912.88.6969.519.47.0966.76.86.9957.47.17.2
긗V with P5P115.418.110.41210.527.28.61514.912.33.31512.04.03.9
긗V without P5P1,2905.810.36.91,3026.612.85.71,4636.56.45.71,4486.76.16.1
Albumin1,3021,3051,4631,447
귾ye binding (BCG)1,2065.25.43.91,2183.85.65.21,3825.04.95.11,3664.95.75.1
귾ye binding (BCP)117.97.32.6102.15.55.392.94.76.9105.13.15.0
긐ther method854.55.53.9773.86.15.2724.74.86.4715.06.06.7
Alkaline phosphatase1,2401,2441,4011,389
긐ther method11151.257.252.810945.161.940.911943.943.638.811644.840.938.4
긑NPP (AMP buffer)65823.117.221.766016.723.218.175614.214.217.275514.917.517.0
긑NPP (DEA buffer)14011.418.810.514312.120.512.214712.212.09.614914.511.612.4
긑NPP (EAE buffer)3316.48.46.03325.415.65.63795.85.84.93696.75.34.8
Amylase733733798788
긅ydrolysis of 2-chloro-p-nitrophenyl-慣-D-maltotrioside (CNP-G3)2274.45.74.32278.19.78.32415.56.74.32415.05.14.7
긅ydrolysis of 4,6-ethylidene-4-nitrophenyl (4-NP)-maltohetaose (G7) substrate2643.212.63.32642.57.53.52833.12.13.32732.53.63.2
긅ydrolysis of 4-nitrophenyl (4-NP)-maltohetaose (G7) substrate47.411.34.031.07.71.152.02.51.965.94.91.0
긐ther method23821.913.718.023917.612.222.526913.013.620.026813.220.220.1
Aspartate aminotransferase1,4141,4191,5841,568
긂nzymatic, colorimetric (Vitros)109.34.45.9104.76.02.9112.53.60.7114.22.72.7
긐ther method1006.812.78.6928.313.36.7914.95.45.0906.95.66.2
긗V with P5P1111.321.818.21218.724.86.4155.03.12.5153.35.55.1
긗V without P5P1,2935.25.56.61,3056.49.15.31,4675.45.24.31,4525.54.74.5
Bilirubin (direct)723723783773
귽olorimetric test (DCA/DPD)1811.410.610.01712.63.79.51412.312.912.1154.513.313.7
귾iazonium salt/diazonium ion with blank24812.19.24.72514.39.414.327822.719.53.827818.35.06.3
긂nzymatic bilirubin oxidase1410.415.716.2159.62.215.71718.518.214.1172.715.113.3
긂velyn-Malloy method with blank1934.632.515.91813.427.517.52432.535.817.52228.914.614.5
긂velyn-Malloy method without blank1121.313.426.3922.230.133.41016.414.924.41016.614.616.3
긇endrassik-Grof method with blank313.411.217.3320.828.718.7322.827.317.7327.514.519.4
긐ther method9327.831.320.28714.121.725.68023.821.136.7765.738.035.4
긐ther method (modified Jendrassik-Groff using surfactant as an accelerator)449.972.169.2525.733.731.5821.336.134.71019.328.614.4
긐xidation239.012.20.7247.00.03.2260.02.54.22619.85.46.9
긐xidation direct bilirubin56.122.28.9317.315.714.4539.139.10.0522.86.76.7
긘anadate oxidation28511.914.010.92918.94.37.031814.312.713.13113.511.213.2
Bilirubin (total)1,3051,3081,4671,451
귽olorimetric test (DCA/DPD)378.111.29.9396.85.96.9426.75.76.2427.56.75.7
귾iazo-dimethyl sulfoxide with blank578.115.518.86214.315.36.1726.37.95.17610.74.85.3
귾iazonium salt/diazonium ion with blank3745.77.78.23746.89.85.540510.111.46.340412.86.06.3
귾iazonium salt/diazonium ion without blank298.910.011.3337.411.88.13813.818.013.83814.410.810.6
귾iazonium salt-dyphylline (Vitros)103.012.912.097.121.42.91110.613.66.01110.25.25.6
긂nzymatic bilirubin oxidase254.66.34.3275.51.75.2309.68.05.93011.15.45.5
긂velyn-Malloy method with blank538.611.39.4508.28.79.86110.79.56.6579.67.67.5
긂velyn-Malloy method without blank747.815.514.37212.113.98.59712.517.76.89416.65.56.3
긇endrassik-Grof method with blank72.313.60.072.012.58.293.26.810.4914.810.611.9
긐ther method8810.39.812.28110.012.37.47816.714.38.67717.39.68.7
긐xidation894.84.34.5864.71.14.57610.610.76.77712.37.27.0
긘anadate oxidation4595.76.17.64655.74.85.35465.54.34.85345.84.84.4
Calcium661663712702
귺rsenazo III dye1063.05.32.61113.04.63.11373.52.93.21323.63.23.1
귽resolphthalein complexone4062.33.42.64051.73.01.94163.73.02.54123.72.72.9
긎methylxylenol blue method181.53.53.3181.42.71.5202.42.01.3191.72.01.4
긏M-BAPTA1091.21.91.51091.51.81.21180.91.31.21191.01.10.7
긐ther method202.75.66.5186.57.45.2206.45.03.5194.44.73.2
Chloride876878986977
긆SE, diluted (indirect)5061.73.42.45092.43.61.75343.62.82.05342.82.02.2
긆SE, undiluted (direct)3322.02.62.23312.22.71.84092.42.22.64022.32.72.6
긐ther method382.43.62.5382.83.02.2433.11.72.1412.52.92.5
Cholesterol (total)1,4071,4111,5721,557
긂nzymatic1,2992.63.12.91,3132.73.22.91,4733.02.84.91,4592.95.24.9
긐ther method1083.54.03.7983.83.13.6993.33.24.5983.95.24.9
Creatine kinase622614654652
긐ther method579.08.86.2527.48.17.2524.54.94.8546.45.95.5
긓everse (CrP넂Cr) reaction2574.25.05.42524.44.74.12664.24.13.12654.13.23.1
긓everse (CrP넂Cr) reaction with cofactor3086.25.86.53106.46.06.23364.33.95.83334.15.96.0
Creatinine1,3531,3581,5241,514
귽ompensated kinetic Jaffe method1483.815.05.81664.213.24.131512.210.36.73207.96.86.2
긂nzymatic method503.29.04.5574.97.53.96335.315.45.26012.04.95.1
긊inetic Jaffe method8455.69.27.38336.76.95.981910.16.77.08086.77.16.9
긐ther method9611.512.112.7869.314.67.88711.011.410.88514.011.112.0
긓ate blanked compensated kinetic Jaffe method2143.66.94.82163.85.23.52406.25.53.92415.73.84.3
Gamma-glutamyl transferase1,3851,3881,5401,525
긄-glutamyl-carboxy-nitroanilide (IFCC)8725.09.55.48835.39.25.19627.37.37.69597.88.08.1
긄-glutamyl-carboxy-nitroanilide (JSCC)2702.96.03.32773.05.12.63202.21.52.13142.62.22.2
긄-glutamyl-p-nitroanilide131.513.85.5114.55.14.7228.43.76.1218.67.26.1
긄-glutamyl-p-nitroanilide (dry chemistry)806.29.66.2815.87.76.3977.47.77.1967.17.26.9
긐ther method1507.711.88.01367.211.96.91398.67.47.01357.06.97.1
Glucose1,3991,4031,5611,544
긄lucose oxidase3233.64.84.13284.75.64.33835.05.04.23795.04.34.4
긅exokinase9752.72.12.99832.72.32.51,0873.22.82.61,0763.12.82.9
긐ther method1014.76.35.0924.76.14.8914.35.04.4893.93.83.8
High density lipoprotein cholesterol1,3081,3091,4471,432
귻eckman AU HDL direct method1643.93.23.11654.03.73.91753.63.25.61753.85.63.5
귾enka HDL direct method615.528.24.245.39.48.3411.79.08.954.97.96.8
귾irect method (other company)35022.928.215.136016.632.423.742414.312.912.642312.612.811.9
긊yowa HDL direct method763.34.44.5775.45.45.8765.94.46.6754.17.96.9
긐ther method10724.929.813.39610.226.622.19714.812.613.39412.313.814.5
긓oche HDL direct method2165.23.43.92163.62.86.02323.83.63.22323.63.53.6
긕ekisui HDL direct method2974.14.03.43023.64.54.33372.83.72.93304.24.53.0
긕iemens Advia direct HDL method382.84.63.3374.36.25.6424.43.20.0423.83.43.4
긕iemens HDL direct method51.75.55.457.57.36.5512.012.314.859.18.78.5
긙ako HDL direct method487.96.56.7466.98.49.2549.610.56.2508.77.17.8
Iron388393408406
귻athophenanthroline without deproteinization1302.22.02.01361.51.81.21361.21.32.31341.52.22.7
긃errachrome/ferrozine without deproteinization1393.62.93.41333.03.13.31412.62.23.41382.02.42.7
긏itroso-PSAP without deproteinization341.81.72.2352.22.21.8361.30.81.3351.22.51.5
긐ther method123.25.84.4123.93.14.1146.75.56.0163.76.27.6
긖ripyridyltriazine-without prior protein removal691.52.02.2731.72.21.5771.21.22.8791.22.22.5
Lactate dehydrogenase830824886878
귾initrophenyl hydrazine (DNPH)420.911.213.940.91.31.653.83.83.554.84.65.0
긌actate to pyruvate3993.95.34.23956.87.36.64465.05.65.64355.15.75.6
긐ther method4736.236.633.04435.235.334.84630.031.332.14931.534.334.5
긑yruvate to lactate3759.18.17.93767.77.09.03836.96.56.73837.16.96.9
긑yruvate to lactate (dry chemistry)52.33.02.052.58.31.162.01.30.864.62.41.8
Lipase394392406400
긅ydrolysis of 1,2-O-dilauryl-rac-glycero-3-glutaric acid-(6-methylresorufin) ester2716.311.86.02688.79.79.02757.75.111.22666.810.08.7
긅ydrolysis of 1-oleoyl-2,3-diacetyl glycerol103.34.24.4103.03.06.4102.53.63.1103.52.70.0
긐ther method4015.333.516.84215.022.814.5439.47.712.44512.215.915.7
긕pectrophotometric method with triglyceride683.67.13.9674.33.92.9741.42.02.0753.52.42.6
Low density lipoprotein cholesterol833829903890
귻eckman AU LDL direct method1057.18.86.61046.79.78.81116.56.86.81126.76.97.3
귾irect method (other company)15725.934.314.516114.736.223.21909.29.310.91909.710.910.3
긊yowa LDL direct method662.75.43.0672.66.22.9652.21.52.9642.22.72.5
긐ther method4932.350.216.94315.351.526.14511.711.512.34010.413.912.2
긓oche LDL direct method1694.89.73.51682.58.24.31754.24.84.81735.44.74.5
긕ekisui LDL direct method2044.17.63.32073.18.73.52322.62.83.52272.83.23.0
긕iemens Advia direct LDL method382.04.71.7373.75.63.8412.83.23.1412.33.13.9
긕iemens LDL direct method46.97.84.042.67.73.945.03.53.546.76.14.3
긙ako LDL direct method388.66.78.6356.37.76.9385.15.03.0365.86.36.9
Magnesium267272283282
귽olorimetrc test-xylidyl blue282.30.02.9273.34.92.1273.43.12.3283.11.71.9
귽olorimetric-Vitros Chemistry Systems43.84.62.540.05.82.247.15.90.043.52.32.3
귽olorimetric (dye-xylidyl blue/magon)2262.25.23.52323.24.62.32423.93.83.42404.02.22.6
긐ther method53.611.61.952.23.66.368.18.35.864.36.57.9
Osmolality129135143143
긃reezing point depression osmometer1141.21.51.61201.31.21.41281.61.31.11271.31.31.3
긐ther method151.21.51.7150.81.21.0151.61.41.1161.81.41.3
Phosphorus617617664658
긐ther method203.55.15.9205.18.94.7224.34.32.8223.63.52.9
긑hosphomolybdate with any reduction method1263.76.03.51283.05.82.71362.32.22.01372.01.81.2
긑hosphomolybdate (UV)4703.05.23.04682.04.62.55052.52.32.24982.42.32.3
Potassium888891999990
긆SE, diluted (indirect)5091.72.91.85131.63.11.35371.71.81.55371.81.71.5
긆SE, undiluted (direct)3412.55.42.23402.14.22.74192.02.22.54122.62.62.2
긐ther method383.14.23.3382.86.12.5432.01.92.2412.12.82.5
긑rotein (total)1,2841,2901,4471,429
귻iuret method1,1953.43.33.11,2102.32.23.31,3712.83.23.71,3553.24.13.7
긐ther method895.34.24.7804.53.75.9764.95.45.4745.04.96.2
Sodium888890999990
긆SE, diluted (indirect)4551.11.31.24650.70.81.04901.01.01.24921.21.11.2
긆SE, undiluted (direct)3911.92.01.93841.72.11.84641.41.41.44541.31.71.7
긐ther method422.31.71.6411.42.02.1451.21.61.7441.61.72.0
Total CO2177185199199
긆SE, diluted (indirect)515.020.916.8422.223.716.723.82.86.423.36.11.0
긐ther method139.713.510.1129.911.67.5139.27.49.81312.412.212.7
긑hosphoenolpyruvate carboxylase (PEPC)1596.58.16.71699.19.37.51845.75.35.51845.75.35.2
Total iron-binding capacity350356371369
귻athophenanthroline1132.33.12.71182.93.52.61221.71.93.01202.12.82.8
귽hromazural B201.52.21.9183.52.32.9194.33.72.7192.84.03.9
긃errachrome/ferrozine1032.85.43.51002.94.33.01052.92.83.81023.23.13.4
긏itroso-PSAP881.82.62.2932.63.52.3982.42.32.4992.41.82.0
긐ther method257.59.18.9266.38.95.0255.14.67.7274.23.44.2
Triglyceride1,37913811,5311,516
긂nzymatic (glycerol phosphate oxidase) with glycerol blank4524.721.85.54544.823.16.84892.92.83.34773.03.23.1
긂nzymatic (glycerol phosphate oxidase) without glycerol blank8214.612.64.28304.511.64.39474.24.26.49464.57.16.4
긐ther method10638.247.826.49728.258.347.4955.45.76.6936.17.06.6
Urea nitrogen1,3501,3491,5111,497
귽onductivity rate method43.10.93.231.49.72.327.93.60.626.50.51.7
긂nzymatic UV test (urease-GLDH)677.86.65.3675.08.64.3745.86.75.5737.26.86.1
긐ther method956.711.56.2865.27.97.8836.35.96.0828.07.05.7
긗rease quinolinium dye (Vitros)91.30.04.392.21.91.992.12.30.592.91.22.1
긗rease with GLDH (coupled enzymes)1,1725.04.14.21,1804.05.45.51,3365.24.74.21,3245.65.54.8
긗rease-indophenol (Berthelot)30.56.91.841.90.70.874.76.55.671.14.14.1
Uric acid1,1031,0981,2011,191
긐ther method715.67.25.8676.97.55.5735.54.84.8714.83.04.6
긗ricase1,0254.57.24.61,0244.25.84.41,1223.94.03.71,1144.04.13.6
긗ricase (Vitros)71.50.00.074.32.84.662.03.02.062.72.91.8

Abbreviations: UV, ultra violet; P5P, pyridoxal-5-phosphate; BCG, bromocresol green; BCP, bromocresol purple; PNPP, para nitrophenylphosphate; AMP, 2-amino-2-methyl-1-propanol; DEA, diethanolamine; EAE, 2-ethylaminoethanol; CNP, C-type natriuretic peptide; DCA, deoxycholic acid; DPD, 2,5-dichlorophenyl diazonium; NM-BAPTA, 5-nitro-5-methyl-(1,2-bis(o-aminophenoxy)ethan-N,N,N,N-tetraacetic acid; ISE, ion-selective electrodes; CrP, creatine phosphate; Cr, creatine; IFCC, International Federation of Clinical Chemistry; JSCC, Japanese Society for Clinical Chemistry; HDL, high-density lipoprotein; nitroso-PSAP, 2-nitroso-5-(N-propyl-N-sulfopropylamino)-phenol; LDL, low-density lipoprotein; GLDH, glutamate dehydrogenase..

*Number of laboratories that participated in the Korean External Quality Assessment Service 2017.


슂솕븰寃궗빆紐 以 븣遺誘, 룷룄떦, 씤(phosphorus)怨 떒諛깆 痢≪젙踰뺤쓽 遺꾪룷媛 씪諛섑솕븰寃궗 李⑥씠媛 엳뿀떎. 븣遺誘쇱쓽 痢≪젙踰뺤쑝濡쒕뒗 immunoturbidimetry踰뺤씠 二쇰줈 씠슜릺뿀怨 떒諛깆쓽 痢≪젙踰뺤쑝濡 dye binding using pyrogallol red踰뺢낵 turbidimetry using benzethonium chloride踰뺤씠 씠슜릺뿀떎. 룷룄떦怨 씤寃궗뿉뒗 媛곴컖 hexokinase踰뺢낵 phosphomolybdate, UV踰뺤씠 씠슜릺뿀떎(Table 8).

Table 8 . Distribution of analytical methods (principle) participated and coefficients of variation (%) according to urine chemistry principles in 2017.

꺿꺿긆tems/methodsTrials

1st2nd


Lab*CUC-17-01CUC-17-02CUC-17-03LabCUC-17-04CUC-17-05CUC-17-06
Albumin123134
긆mmunoturbidimetry11434.136.622.712343.821.922.1
긐ther method650.354.727.9753.035.437.8
Calcium117130
귺rsenazo III dye123.73.72.9164.43.22.7
귽resolphthalein complexone663.53.32.5742.12.42.3
긏M-BAPTA342.23.21.9362.52.11.6
Chloride131147
긆SE, diluted (indirect)1288.19.43.21448.72.72.8
긐ther method36.57.51.230.23.32.7
Creatinine142160
귽ompensated kinetic Jaffe method372.73.83.1413.72.83.7
긂nzymatic method73.02.34.295.15.53.9
긊inetic Jaffe method384.73.45.0455.24.65.3
긓ate blanked compensated kinetic Jaffe method592.73.63.4642.93.22.5
Glucose111122
긅exokinase1093.13.42.41213.72.42.7
Magnesium96100
귽olorimetrc test-xylidyl blue98.17.47.193.68.411.5
귽olorimetric (dye-xylidyl blue/magon)863.44.26.2893.25.14.7
Phosphorus113121
긑hosphomolybdate (UV)1123.03.13.81192.82.72.9
Potassium132148
긆SE, diluted (indirect)1292.32.74.21452.44.04.3
Protein129143
귻iuret method612.110.49.268.96.74.7
귾ye binding using pyrogallol red7116.716.510.68015.19.810.9
긖urbidimetry using benzethonium chloride505.76.95.0555.64.04.0
Sodium132149
긆SE, diluted (indirect)1292.52.51.21462.41.21.2
Urea nitrogen121135
긂nzymatic UV test (urease-GLDH)72.02.58.0105.84.33.8
긗rease with GLDH (coupled enzymes)1143.43.23.31253.43.33.3
Uric acid116126
긗ricase1144.85.64.31254.63.73.6

Abbreviations: NM-BAPTA, 5-nitro-5-methyl-(1,2-bis(o-aminophenoxy)ethan-N,N,N,N-tetraacetic acid; ISE, ion-selective electrodes; UV, ultra violet; GLDH, glutamate dehydrogenase..

*Number of laboratories that participated in the Korean External Quality Assessment Service 2017.


2017뀈 씪諛섑솕븰寃궗 봽濡쒓렇옩怨 슂솕븰寃궗 봽濡쒓렇옩쓽 떊鍮숇룄議곗궗 寃곌낵뿉 빐 蹂대떎 옄꽭븳 넻怨꾨텇꽍 寃곌낵뒗 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽 솃럹씠吏(http://eqas.keqas.org)뿉꽌 議고쉶媛 媛뒫븯떎. 媛 湲곌쓽 떊鍮숇룄議곗궗 寃곌낵뿉 븳 빐꽍怨 寃궗踰 꽑깮 떆 蹂 넻怨꾨텇꽍 옄猷뚭 쑀슜븷 寃껋쑝濡 깮媛곷맂떎.

References
  1. Lee YW, Jeon BR, Kim JG, Jun SH, Yun YM, Chun S, et al. Annual report on the external quality assessment scheme for routine clinical chemistry in Korea (2016). J Lab Med Qual Assur 2017;39:61-75.
    CrossRef
  2. Jun SH, Song J, Song WH, Clinical Chemistry Subcommittee Korean Association of External Quality, Assessment Service. Annual report on the external quality assessment scheme for clinical chemistry in Korea (2015). J Lab Med Qual Assur 2016;38:111-9.
    CrossRef
  3. Jun SH, Song J. Clinical Chemistry Subcommittee, The Korean Association of External Quality Assessment Service. Annual report on the external quality assessment scheme for clinical chemistry in Korea (2014). J Lab Med Qual Assur 2015;37:115-23.
    CrossRef